Ethnic variations in lipid-lowering in response to a statin (EVIREST): A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Ethnicity and Disease

Volumn 21, Issue 2, 2011, Pages 150-157

  Chapman, Neil ^a   Chang, Choon Lan ^a   Caulfield, Mark ^b   Dahlof̈, Bjor̈n ^c   Feder, Gene ^d   Sever, Peter S ^a   Poulter, Neil R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cholesterol; Ethnic groups; Lipid levels; Statins

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AFRICAN CARIBBEAN; ARTICLE; ASIAN; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; ETHNIC DIFFERENCE; FEMALE; HUMAN; HYPERTENSION; IRELAND; MAJOR CLINICAL STUDY; MALE; NEGRO; PLACEBO EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ETHNOLOGY; FOLLOW UP; HYPERCHOLESTEROLEMIA; MIDDLE AGED; RACE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; CONTINENTAL POPULATION GROUPS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; IRELAND; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 80053338005     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Baigent C, Keech A, Kearney P, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
2. Jacobson T, Chin M, Curry C, et al. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Arch Intern Med. 1995;155:1900-1906.
3. Prisant L, Downton M, Watkins L, et al. Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. Am J Cardiol. 1996;78:420-424. (Pubitemid 26277021)
4. Zhu J, Tomlinson B, Ro Y, Sim K, Lee Y, Sriratanasathavorn C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY- Asia study). Curr Med Res Opin. 2007; 23:3055-3068.
5. Liao J. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410-414. (Pubitemid 46149563)
6. Itoh T, Matsumoto M, Hougaku H, et al. Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group. Clin Ther. 1997;19: 487-497. (Pubitemid 27292589)
7. Tan C, Loh L, Tai E. Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience. Singapore Med J. 2003;44: 635-638. (Pubitemid 38387322)
8. Patel J, Gupta S, Lie F, Hughes E. Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study. Vasc Health Risk Manag. 2005;1:351-356.
9. Deedwania P, Gupta M, Stein M, Ycas J, Gold A. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol. 2007;99:1538-1543. (Pubitemid 46770637)
10. Chung N, Cho S, Choi D, et al. STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target. Clin Ther. 2001;23:858-870. (Pubitemid 32554568)
11. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in White and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330-341. (Pubitemid 41393668)
12. Krauss R, Mangravite L, Smith J, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008;117:1537-1544. (Pubitemid 351440642)
13. Shear C, Franklin F, Stinnett S, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation. 1992;85:1293-1303.
14. Morales D, Chung N, Zhu J, et al. Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies. Curr Med Res Opin. 2004;20:1235-1243. (Pubitemid 39120788)
15. Erdine S, Ro Y, Tse H, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens. 2009;23:196-210.
16. Poulter N, Caulfield M, Feder G. Ethnic variations in response to a statin (EVIREST). J Hum Hypertens. 2001;15(Suppl 1):S87-89. (Pubitemid 32904119)
17. Sever P, Dahlöf B, Poulter N, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 2001;19:1139-1147. (Pubitemid 32493649)
18. Sever P, Dahlöf B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158. (Pubitemid 36398384)
19. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):v1-52.
20. Kushiro T, Mizuno K, Nakaya N, et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension. 2009;53:135-141.
21. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42:1208-1215.
22. Ashworth M, Lloyd D, Smith R, Wagner A, Rowlands G. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health (Oxf). 2007;29:40-47.
23. Wong N, Lopez V, Tang S, Williams G. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98: 204-208. (Pubitemid 43996906)
24. Yood M, McCarthy B, Kempf J, et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J. 2006;152:777-784. (Pubitemid 44396880)
25. Clark L, Maki K, Galant R, Maron D, Pearson T, Davidson M. Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med. 2006;21:320-326.
26. Jha A, Varosy P, Kanaya A, et al. Differences in medical care and disease outcomes among Black and White women with heart disease. Circulation. 2003;108:1089-1094. (Pubitemid 37071519)
27. Kaplan R, Bhalodkar N, Brown EJ, White J, Brown D. Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications. Prev Med. 2004; 39:1249-1255. (Pubitemid 39468643)
28. Williams M, Morris MT, Ahmad U, Yousseff M, Li W, Ertel N. Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center. Ethn Dis. 2002;12:S1-58-62.
29. Mück W, Unger S, Kawano K, Ahr G. Interethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol. 1998;45:583-590. (Pubitemid 28270914)